NASDAQ · ARTL
Artelo Biosciences, Inc.
$2.31-$0.02 (-0.86%)
Artelo Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.71% below the high.
Loading market information…
NASDAQ · VRAX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Virax Biolabs Group Limited’s quoted price sits in the lower half of its reported 52-week range, 93.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Virax Biolabs Group Limited’s next earnings report is currently expected on Dec 2, 2026, with estimated earnings per share of -$1.75. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Virax Biolabs Group Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:37 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Jan 12, 2024 |
| -$41.00 |
| $76.50K-80.88% vs estimate |
| Q4 2023 | Jun 14, 2023 | -$64.50 | $2.80K-98.6% vs estimate |
|---|
| Q3 2023 | Feb 2, 2023 | -$31.00 | $5.76K |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.31-$0.02 (-0.86%)
Artelo Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.71% below the high.
$5.60+$0.09 (+1.63%)
GT Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.52% below the high.
$0.84-$0.03 (-3.84%)
Dermata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.95% below the high.
$2.64+$0.07 (+2.72%)
PMGC Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.82% below the high.
$1.03-$0.02 (-1.9%)
XORTX Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.39% below the high.
$0.01$0.00 (0.0%)
NKGen Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.56% below the high.
$0.38$0.00 (0.0%)
Avenue Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.8% below the high.
$2.69-$0.01 (-0.3%)
NewcelX Ltd.’s quoted price sits in the lower half of its reported 52-week range, 67.57% below the high.
